| Enzon Pharmaceuticals, Inc |
685 Route 202/206 | |
Bridgewater, NJ 08807 | |
Phone: 908 541 8600 | |
Fax: 908 575-9457 | |
www.enzon.com |
June 14, 2007
NatImmune A/S
Fruebjergvej 3 box 3
DK-2100 Copenhagen Ø
Denmark
Re: | Amendment to License Agreement between NatImmune A/S (“NatImmune”) and Enzon Pharmaceuticals, Inc. (“Enzon”) dated September 30, 2005 (the “Agreement”) |
Gentlemen:
We are writing to confirm the agreement between NatImmune and Enzon that:
(i) Section E of Schedule 3.4(b) of the Agreement is deleted and replaced in its entirety by the following:
1. [**Redacted**].
The listing of the above services shall not imply an obligation on the part of Enzon to conduct or commission any activities by the third parties referred to above.
[**Redacted**]
The above described parameters shall not be modified, amended or waived by Enzon unless set forth in writing signed by Enzon’s Chief Executive Officer.
(ii) Section 2.3 of the Agreement concerning the terms for an agreement respecting the Baltic Countries, which provision was previously amended, be further amended such that “September 30, 2006” be changed to “March 31, 2008”.
All other terms of the Agreement shall remain unchanged. Capitalized words used in this letter that are not defined in this letter shall have the meanings ascribed to them in the Agreement.
Please sign below to acknowledge your agreement with the foregoing.
Yours truly,
ENZON PHARMACEUTICALS, INC. |
|
| ||
|
|
| ||
|
|
| ||
By: | /s/ Jeffrey H. Buchalter |
|
|
|
|
|
|
| |
Name: Jeffrey H. Buchalter |
|
|
| |
Title: Chairman, President and Chief Executive Officer |
|
|
| |
June 14, 2007
NatImmune A/S
Page 2
Accepted and agreed by:
NATIMMUNE A/S |
|
| ||
|
|
| ||
By: | /s/ Martin Bonde |
| By: | /s/ Claus Berner Møller |
|
|
| ||
Name: Martin Bonde |
| Name: Claus Berner Møller | ||
Title: Chief Executive Officer |
| Title: Chairman | ||